Caribou Biosciences Stock
Caribou Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Rachel E. Haurwitz
- Employees
- 97
- Market cap
- $50 M
- IPO
- 23/07/2021
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and…
Caribou Biosciences stock: price history
1D
+1.1%
1W
+2.1%
1M
-62.4%
6M
-78.6%
YTD
-70.4%
1Y
-82.4%
2Y
-77.2%
5Y
-97.7%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~11% stronger price swings than usual
Caribou Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Caribou Biosciences
Analyst assessment of Caribou Biosciences
PRICE TARGET LOW
US$1.00
CONSENSUS
US$1.00
MEDIAN
US$1.00
PRICE TARGET HIGH
US$1.00
0
STRONG BUY
6
BUY
4
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 08/10/2026
Caribou Biosciences stock metrics
P/E
-0.44
P/B
0.48
EV/EBITDA
-0.49
RETURN ON EQUITY
-24.8%
NET MARGIN
-1,619.9%
DEBT/EQUITY
0.27
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.0%
FLOAT SHARES
97,558,422
AVG. DAILY VOLUME (30D)
3,893,157
Institutional holders
Comparable stocks
Frequently asked questions about Caribou Biosciences stock
What does Caribou Biosciences do?
Caribou Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Rachel E. Haurwitz, the company employs around 97 people.
The IPO was on 23/07/2021; the stock trades on NASDAQ under the ticker CRBU.
What do analysts say about Caribou Biosciences stock?
10 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$1.00, ranging from US$1.00 to US$1.00, with a median of US$1.00.
This is an external assessment, not a statement by Market Jury.
When does Caribou Biosciences report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 11% stronger than usual.
Does Caribou Biosciences pay a dividend?
No, Caribou Biosciences currently does not pay a dividend.
Which stocks are comparable to Caribou Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Caribou Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Caribou Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.